Takeda Pharmaceutical Co., Ltd: PharmaVitae Profile
Introduction
This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
Strategic insight into the prospects for Takeda over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Takeda's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Strategic insight into the prospects for Takeda over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Takeda's performance against key rivals in the prescription pharmaceutical sector
- Discover if Takeda will overcome generic competition facing its biggest selling medications
- Investigate the diverse strategies being employed by Japan's oldest and largest pharmaceutical player
Contents
Executive SummaryKey findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Takeda: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
Follow-on therapies vital in limiting impact of generic penetration
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest prescription pharma product news
Q1 2010
Latest corporate news
Q1 2010
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
Out-licensing and TAP joint venture provide initial framework for US penetration
Japanese healthcare reforms heighten competition in domestic market
Consumer health
M&A history
Acquisition of Paradigm Therapeutics
Acquisition of Syrrx
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS
Overview
Dexilant
Blopress/Blopress Comp
Actos/ACTOplus met
Lupron Depot
Velcade
Alogliptin franchise
Enbrel
Amitiza
APPENDIX
References
Abbreviations
Exchange rates Skip to top